Our hope never dies.

Developing innovative drugs
for the treatment of cancers
and autoimmune disease

Tiziana Life Sciences Plc

Founded in 2013 and listed on the UK AIM market Tiziana Life Sciences plc is focused on designing and developing targeted, next generation therapeutics and diagnostics to treat cancers, immune disease and inflammation.

Our Therapeutic Focus

Tiziana Life Sciences is focused on serious diseases of high unmet need within the fields of cancers, autoimmune disorders and inflammation.



  • Thymoma and thymic carcinoma are rare malignant tumours of the thymus, an organ that forms part of the immune system and sits just behind the sternum.
  • One third of tumours are discovered because the patient has an associated autoimmune disorder.
  • Our investigational therapy, milciclib, for thymoma has been granted orphan designation by the European Medicine's Agency.


  • Hepatocellular carcinoma (HCC) is among the 10 most common cancers worldwide and the most common type of liver cancer. It occurs more frequently in men than in women and is generally preceded by long term liver disease and cirrhosis (scarring).
  • Primary liver cancer is žthe third most common cause of cancer mortality, with a very low five-year survival rate, generally less than 10%.
Inflammatory and Autoimmune disease


  • Crohn's Disease is a serious chronic inflammatory condition, primarily affecting the digestive system. More than 50% of patients with Crohn's disease need surgery within 10 years of diagnosis.
  • Crohn's appears to be caused by a combination of factors, both environmental and genetic.
  • Incidence of Crohn's is increasing and currently in around 1 in 10,000 people.


  • Nonalcoholic steatohepatitis (NASH) is an extreme form of fatty liver disease where inflammation and liver damage occurs.
  • Currently affecting 2-5% of people, a global epidemic of obesity is driving an increase in the incidence of this condition.

Our R&D Pipeline

With several candidates in the clinic, our development portfolio is supported by extensive IP and a strong pipeline of in-licensed clinical & pre-clinical assets

Recent News

JAN 3, 2017

Acquisition of an exclusive worldwide license of NI-1201, a fully human anti-IL-6R monoclonal antibody, from Novimmune SA expands our therapeutic pipeline

"We view NI-1201 as a potential game-changer for addressing the high unmet need of autoimmune and inflammatory diseases" commented Gabriele Cerrone, Chairman of Tiziana Life Sciences. "The acquisition of NI-1201 not only strengthens our business strategy of developing novel fully human mAbs to treat life-threatening inflammatory diseases such as non-alcoholic steatohepatitis (NASH) and rheumatoid arthritis, but expands our potential to leverage the pioneering work we are doing with foralumab, the oral anti-CD3 mAb to treat autoimmune and inflammatory diseases."

NOV 16, 2016

New data for foralumab, our fully human anti-CD3 antibody demonstrates the potential of this novel oral therapy

Foralumab, a long half-life therapeutic mAb candidate, with high affinity and potency for CD3 epsilon, has shown consistent efficacy via oral administration in pre-clinical studies conducted by Prof. Kevan Herold, a member of Tiziana's Scientific Advisory Board, at Yale University. "This study demonstrates that oral administration works consistently in our pre-clinical models with human immune cells. This suggests that oral CD3-specific mAb has the potential for treating NASH, diabetes, and other autoimmune diseases in humans - an entirely novel approach for the treatment of currently unmet needs," commented Prof. Kevan Herold.

Contact Us

For any Enquiries,
please call or email us:

+44 (0) 207 495 2379 | info@tizianalifesciences.com


Tiziana Life Sciences plc
55 Park Lane
London W1K 1NA
United Kingdom


Tiziana Life Sciences
420 Lexington Avenue, Suite 2525
New York, NY 10170

R&D Center

Tiziana Life Sciences
Pennsylvania Biotechnology Center of Bucks County
3805 Old Easton RD
Doylestown, PA 18902-8400

Registered Offices

Tiziana Life Sciences plc
3rd Floor, 11-12 St. James's Square
United Kingdom